» Articles » PMID: 10502571

Dry Eye After Haematopoietic Stem Cell Transplantation

Overview
Journal Br J Ophthalmol
Specialty Ophthalmology
Date 1999 Sep 30
PMID 10502571
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: To determine the incidence, natural course, and severity of dry eye occurring or worsening after haematopoietic stem cell transplantation (SCT).

Methods: At a tertiary care hospital, 53 patients undergoing allogeneic or autologous SCT followed by at least 180 days of follow up were studied prospectively. Examination included grading of symptoms of dry eye, evaluation of ocular surface, tear break up time, and Schirmer tests with and without nasal stimulation. Meibomian gland secretion was also examined using a slit lamp while applying steady digital pressure.

Results: Of the 53 patients, 44 received allografts. Half of these patients (22) developed dry eye or their pre-existing dry eye worsened after SCT, while none of nine autograft recipients did. Onset of dry eye was 171 (SD 59) days after SCT. Two types of dry eye occurred. One (n=10) was severe with ocular surface findings resembling Sjögren's syndrome and reduction of reflex tearing soon after onset. A mild type (n=12) had unimpaired reflex tearing. Meibomian gland dysfunction (MGD) was more frequent and severe in patients with dry eye and chronic graft versus host disease (GVHD), and overall severity of dry eye was greater in patients with MGD and chronic GVHD.

Conclusions: Dry eye after SCT occurred only in allograft recipients, and was not evident in autograft recipients. The severe form of dry eye had a tendency to develop rapidly. Further study on the prediction and treatment of severe dry eye after SCT is necessary.

Citing Articles

Application of lacrimal gland ultrasonography in the evaluation of chronic ocular graft-versus-host-disease.

Zhong M, Liu S, Luo J, Zhang Q, Yang Z, Zhang S Front Immunol. 2025; 16:1490390.

PMID: 39975559 PMC: 11836017. DOI: 10.3389/fimmu.2025.1490390.


Erosive Tarsal Conjunctival Lesions Following Immunogenic Events in Early Development of Ocular Graft-vs-Host Disease.

Kohnstam M, Surico P, Luo Z Life (Basel). 2024; 14(10).

PMID: 39459617 PMC: 11509472. DOI: 10.3390/life14101317.


Clinical Manifestations and Outcomes of Ocular Graft Versus Host Disease following Allogeneic Stem Cell Transplantation.

Shetty V, Kashelkar P, Punatar S, Haldipurkar S, Hoshing A, Thakur R J Ophthalmic Vis Res. 2024; 19(3):284-296.

PMID: 39359525 PMC: 11443995. DOI: 10.18502/jovr.v19i3.13095.


The Necroptosis Pathway Is Upregulated in the Cornea in Mice With Ocular Graft-Versus-Host Disease.

Asai K, Lee H, Sato S, Shimizu E, Jung J, Okazaki T Invest Ophthalmol Vis Sci. 2024; 65(10):38.

PMID: 39189995 PMC: 11361379. DOI: 10.1167/iovs.65.10.38.


Ophthalmic Manifestations in Patients with Blood Malignancies.

Rossi C, Buizza A, Alessio G, Borselli M, Taloni A, Carnevali A Hematol Rep. 2024; 16(2):193-203.

PMID: 38651449 PMC: 11036248. DOI: 10.3390/hematolrep16020020.


References
1.
Shulman H, Sullivan K, Weiden P, McDonald G, Striker G, Sale G . Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980; 69(2):204-17. DOI: 10.1016/0002-9343(80)90380-0. View

2.
Shimazaki J, Goto E, Ono M, Shimmura S, Tsubota K . Meibomian gland dysfunction in patients with Sjögren syndrome. Ophthalmology. 1998; 105(8):1485-8. DOI: 10.1016/S0161-6420(98)98033-2. View

3.
Fraunfelder F, Meyer S . Ocular toxicity of antineoplastic agents. Ophthalmology. 1983; 90(1):1-3. DOI: 10.1016/s0161-6420(83)34600-5. View

4.
Franklin R, Kenyon K, Tutschka P, Saral R, Green W, SANTOS G . Ocular manifestations of graft-vs-host disease. Ophthalmology. 1983; 90(1):4-13. DOI: 10.1016/s0161-6420(83)34604-2. View

5.
Hirst L, Jabs D, Tutschka P, Green W, SANTOS G . The eye in bone marrow transplantation. I. Clinical study. Arch Ophthalmol. 1983; 101(4):580-4. DOI: 10.1001/archopht.1983.01040010580010. View